We validated the performance of our previously reported test for bladder cancer based on urine gene expression patterns using an independent cohort.
Approximately, 75%and91%1% of PCPs reported testing for albuminuria in non-diabetic hypertensive patients with an eGFR > 60 ml/min/1.73 m2 and < 60 ml/min/1.73 m2, respectively.
Overall, just under half (48.4 %) of our study population reported testing for HIV in the past year.
Of all participants who reported testing for HIV, 89% used antibody tests, 3% a rapid test and 1% NAAT.
Sixty-one percent reported testing for HIV less than a year earlier at clinic HIV testing centers (Table 1).
Moreover, only two studies reported testing for extended spectrum beta-lactamase (ESBL) despite the fact that ESBL have been reported worldwide.
A lower proportion of Asian MSM reported testing for hepatitis C in the past two years (p = 0.22), but not for gonorrhea (p = 0.080) or syphilis (p = 0.407).
Approximately, 75%and91%1% of PCPs reported testing for albuminuria in non-diabetic hypertensive patients with an eGFR > 60 ml/min/1.73 m and < 60 ml/min/1.73 m, respectively.
Nine studies reported testing for links between additional factors (e.g. client demographics) and treatment satisfaction in DD clients (research question 4).
Authors in 42 studies reported testing for Hardy-Weinberg equilibrium and found no deviation (see Web Table 1 and Table 2).
In non-diabetic hypertensive patients with an eGFR ≥ 60 ml/min/1.75%m, 75% of PCPs reported testing for albuminuria or proteinuria; 51%, 13%, and 10% of PCPs reported performing such testing annually, every 2 3 years, and twice a year, respectively.
